14993-80-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(6-Methylpyridin-2-yl)acetonitrile is utilized as a building block for the synthesis of various pharmaceuticals. Its chemical structure allows for the creation of diverse drug candidates, contributing to the advancement of new treatments and therapies.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(6-Methylpyridin-2-yl)acetonitrile serves as a key intermediate in the development of drugs. Its unique properties enable the design and synthesis of compounds with specific biological activities, facilitating the discovery of novel therapeutic agents.
Used in Drug Discovery Processes:
2-(6-Methylpyridin-2-yl)acetonitrile is employed in drug discovery processes to identify and optimize potential drug candidates. Its presence in the molecular structure can influence the pharmacokinetic and pharmacodynamic properties of the resulting compounds, enhancing their efficacy and safety profiles.
Used in Organic Synthesis:
Beyond its pharmaceutical applications, 2-(6-Methylpyridin-2-yl)acetonitrile also finds use in organic synthesis. Its reactivity and functional group compatibility make it a versatile component in the synthesis of various organic compounds, expanding its utility in chemical research and development.
Used in Materials Science:
2-(6-Methylpyridin-2-yl)acetonitrile may also have applications in materials science, where its unique structural features could contribute to the development of new materials with specific properties. Its potential use in this field highlights the compound's broad applicability across different scientific disciplines.

InChI:InChI=1/C8H8N2/c1-7-3-2-4-8(10-7)5-6-9/h2-4H,5H2,1H3

Upstream product

• 1073-23-0 2,6-lutidine N-oxide 
• 68470-59-7 2-(bromomethyl)-6-methylpyridine 
• 773837-37-9 sodium cyanide 
• 1313735-48-6 (6-methylpyridin-2-yl)methyl 4-methylbenzenesulfonate 
• 7677-24-9 trimethylsilyl cyanide 
• 151-50-8 potassium cyanide 
• 3099-30-7 2-chloromethyl-6-methylpyridine hydrochloride 

Downstream Products

• 19363-94-1 2-(6-methylpyridin-2-yl)ethan-1-amine 
• 944330-93-2 C₅₀H₅₆N₆O₂ 

Relevant academic research and scientific papers

Metal-free C(sp3)-H bond sulfonyloxylation of 2-alkylpyridines and alkylnitrones

Pyridin-2-ylmethyl tosylate derivatives are obtained in high yields from 2-alkylpyridine 1-oxides via a [3,3]-sigmatropic rearrangement of the adduct between 2-alkylpridine 1-oxides with benzenesulfonyl chlorides. Moreover, alkylnitrones also undergo [3,3]-sigmatropic rearrangement to give α-tosylated ketones after hydrolysis. Substitution reactions with nucleophiles then lead to diverse useful functionalizations for the synthesis of pincer ligands.

Alkylation of 2-substituted (6-Methyl-2-pyridyl)methyllithium species with epoxides

Substituted (6-methyl-2-pyridyl)methyllithium species were reacted with 1,2-epoxyoctane and 2-methyl-2,3-epoxynonane. The monosubstituted epoxide reacted efficiently with lutidyllithium and a number of 2-substituted (6-methyl-2-pyridyl)methyllithium deriv

PHARMACEUTICAL COMPOUNDS

The invention provides compounds which are pyrimidines of formula (I): wherein R2 is bonded at ring position 2 and -YR1 is bonded at ring position 5 or 6, or YR1 is bonded at ring position 2 and R2 is bonded at ring position 6; R is an indol-4-yl group which is substituted at the 5- or 6-position; either: (a) Y is selected from -O-(CH2)n-, -NH-(CH2)n-,. -NHC(O)-(CH2)n and -C(O)NH-(CH2)n- wherein n is 0 or an integer of 1 to 3, and R1 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted and a group -NR3R4 wherein R3 and R4, which are the same or different, are each independently selected from H, C1-C6 alkyl which is unsubstituted or substituted, C3 - C10 cycloalkyl which is unsubstituted or substituted, -C(O)R, -C(O)N(R)2 and -S(O)mR, or R3 and R4 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6- or 7- membered N-containing heterocyclic group which is unsubstituted or substituted; (b) Y is a direct bond and R1 is selected from an unsaturated 5- to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted, and a group -NR3R4 wherein R3 and R4, which are the same or different, are each independently selected from H, C1-C6 alkyl which is unsubstituted or substituted, C3-C10 cycloalkyl which is unsubstituted or substituted, -C(O)R, -C(O)N(R)2 and -S(O)mR; R is selected from H, C1-C6 alkyl, C3-C10 cycloalkyl and a 5- to 12-membered aryl or heteroaryl group, which group is unsubstituted or substituted; and m is 1 or 2; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PO K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PB kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.